These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 18488380

  • 1. [The results of wet AMD treatment by intravitreal injections--preliminary report].
    Okruszko A, Borucka AI, Ulińska M, Szaflik J.
    Klin Oczna; 2007; 109(10-12):389-93. PubMed ID: 18488380
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 4. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.
    Klin Oczna; 2007 Jul; 109(10-12):402-9. PubMed ID: 18488382
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [Abstract] [Full Text] [Related]

  • 7. Ranibizumab for the treatment of neovascular AMD.
    Kaiser PK, Do DV.
    Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 9. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 10. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [Abstract] [Full Text] [Related]

  • 11. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
    Kloos P, Bernasconi P, Estermann S, Bachmann B, Rutishauser Y, Thölen A.
    Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S, Rosenfeld PJ.
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [Abstract] [Full Text] [Related]

  • 13. [Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].
    Ambresin A, Mantel I.
    Rev Med Suisse; 2007 Jan 17; 3(94):137-41. PubMed ID: 17354539
    [Abstract] [Full Text] [Related]

  • 14. [The first experience of intravitreal injection of Lucentis (ranibizumab) in the moist form of age-related maculodystrophy].
    Baĭborodov IaV.
    Vestn Oftalmol; 2009 Jan 17; 125(5):31-3. PubMed ID: 19916331
    [Abstract] [Full Text] [Related]

  • 15. [Intravitreal Ranibizumab Injection for the Treatment of Occult and Classic CNV in Exsudative AMD].
    Maier MM, Feucht N, Fegert C, Fiore B, Winkler von Mohrenfels C, Lohmann C.
    Klin Monbl Augenheilkd; 2011 Feb 17; 228(2):161-7. PubMed ID: 20336600
    [Abstract] [Full Text] [Related]

  • 16. First versus second eye intravitreal ranibizumab therapy for wet AMD.
    Eldaly MA, Styles C.
    Retina; 2009 Mar 17; 29(3):325-8. PubMed ID: 19287289
    [Abstract] [Full Text] [Related]

  • 17. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep 17; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 18. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
    Figurska M, Robaszkiewicz J, Wierzbowska J.
    Klin Oczna; 2010 Sep 17; 112(4-6):147-50. PubMed ID: 20825071
    [Abstract] [Full Text] [Related]

  • 19. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.
    Am J Ophthalmol; 2009 Sep 17; 148(3):409-13. PubMed ID: 19477713
    [Abstract] [Full Text] [Related]

  • 20. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
    Parravano M, Oddone F, Tedeschi M, Schiano Lomoriello D, Chiaravalloti A, Ripandelli G, Varano M.
    Retina; 2009 Mar 17; 29(3):329-34. PubMed ID: 19092732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.